RxDoctor Payments Data

Mark Zambron, MD

Internal Medicine · Buffalo, NYNPI 1669435103

Payments from drug & device makers

$529in general payments, 2019–2025

Across 33 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$145
  • Greenwich Biosciences, Inc.$95
  • Pfizer$63
  • Amgen$56
  • Novo Nordisk$53
  • Sanofi-aventis U.S. LLC$30
  • plus $86 from 4 others

What the payments were for

  • Food & beverage$529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$529 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$5,960
Medicare patients
30
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide137$154,573
EliquisApixaban160$95,614
JardianceEmpagliflozin84$59,953
XareltoRivaroxaban51$47,370
OzempicSemaglutide49$46,572
FarxigaDapagliflozin Propanediol55$31,738
MounjaroTirzepatide28$28,802
ProliaDenosumab16$27,116
VascepaIcosapent Ethyl52$23,039
InvokanaCanagliflozin27$20,186
Cyclosporine12$17,865
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$16,643
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$15,278
Incruse ElliptaUmeclidinium Bromide31$14,398
LinzessLinaclotide25$13,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$24$183,375165 claims
PfizerEliquis$63$95,614160 claims
Novo NordiskOzempic$53$46,57249 claims
AstraZenecaFarxiga, Symbicort$145$34,62168 claims
GSKAnoro Ellipta, Incruse Ellipta, Breo Ellipta$12$34,32659 claims
AmgenProlia$56$27,11616 claims
MerckJanuvia$25$11,63813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →